Sugi Predict

Sugi Predict / Compounds / SCHEMBL169646

SCHEMBL169646

SCHEMBL169646

NC(=O)Nc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.61
▸ PTGS1 P23219 3/20 0.59
▸ ALPI P09923 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ XIAP P98170 1/20 0.59
▸ ITGB3 P05106 1/20 0.55
▸ ITGAV P06756 1/20 0.55
▸ ITGA2B P08514 1/20 0.55
▸ TPH1 P17752 1/20 0.55
▸ MAPT P10636 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ GFER P55789 1/20 0.53
▸ CYP3A4 P08684 3/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ HIF1A Q16665 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ ABCB11 O95342 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169645 1.00 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1932906 1.00 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31370437 0.95 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL180331 0.87 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL180332 0.87 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL289162 0.87 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8423623 0.87 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4943107 0.86 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL30037334 0.86 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL3059437 0.86 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024121249-A1 ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS ARICEUM THERAPEUTICS GMBH (DE) 2024-06-13 — — WO claimed
EP-2801582-B1 Somatostatin receptor 2 antagonists SALK INST FOR BIOLOGICAL STUDI (US) 2017-09-06 — — EP claimed
EP-2383289-B1 Receptor (SSTR2)-selective somatostatin antagonists SALK INST FOR BIOLOGICAL STUDI (US) 2014-10-08 — — EP claimed
EP-2433963-B1 Receptor (SSTR2)-selective somatostatin antagonists SALK INST FOR BIOLOGICAL STUDI (US) 2014-06-04 — — EP claimed
EP-2076535-B1 RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS SALK INST FOR BIOLOGICAL STUDI (US) 2013-03-06 — — EP claimed
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2025-12-02 — — US disclosed
EP-4630064-A1 ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS Ariceum Therapeutics GmbH (DE) 2025-10-15 — — EP disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 — — US disclosed
WO-2024121249-A1 ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS ARICEUM THERAPEUTICS GMBH (DE) 2024-06-13 — — WO disclosed
CN-116284236-B The method comprises the following steps of 18 F-nuclein labeled somatostatin receptor inhibitor probe, preparation method thereof and kit 中国医学科学院北京协和医院 2024-02-20 — — CN disclosed
US-20240041972-A1 CONJUGATES FOR IMMUNOTHERAPY UNIVERSITY OF SOUTH FLORIDA 2024-02-08 — — US disclosed
US-11826397-B2 Method of treating prostate cancer with GnRH antagonist FERRING B.V. (NL) 2023-11-28 — — US disclosed
US-20090203622-A1 METHOD OF TREATING METASTATIC STAGE PROSTATE CANCER FERRING INTERNATIONAL SA. 2009-08-13 — — US disclosed
US-20090203623-A1 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST FERRING INTERNATIONAL SA 2009-08-13 — — US disclosed
EP-2076535-A2 RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2009-07-08 — — EP disclosed
US-20080299040-A1 SOMATOSTATIN RECEPTOR 2 ANTAGONISTS SALK INSTITUTE FOR BIOLOGICAL STUDIES UNIVERSITAT BERN UNIVERSITY HOSPITAL BASEL 2008-12-04 — — US disclosed
US-20080260638-A1 RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-10-23 — — US disclosed
WO-2008048942-A2 RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-04-24 — — WO disclosed
US-6875843-B2 Prevention of diabetes and prolongation of the honeymoon phase of diabetes by administration of GnRH antagonists CHILDREN'S MERCY HOSPITAL (US) 2005-04-05 — — US disclosed
US-20030045475-A1 Prevention of diabetes and prolongation of the honeymoon phase of diabetes by administration of GnRH antagonists JACOBSON JILL D (US) 2003-03-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080260638-A1 RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS SSTR5, SSTR4, SSTR3 SLC7A5 85/4885PTGS1 4381/4885ALPI 4180/4885
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 SLC7A5 3196/4885PTGS1 671/4885ALPI 546/4885
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 SLC7A5 1032/4885PTGS1 2711/4885ALPI 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.